Skip to main content

Nicox Reports Positive Results of Secondary Analyses from Phase 2 Trial Further Highlighting Potential of NCX 470 in Glaucoma

Written by Customer Service on . Posted in Public Companies.


APPENDIXComprehensive Clinical Results from the Dolomites StudyNCX 470 (0.021%, 0.042%, and 0.065%) met pre-specified primary efficacy endpoint of non-inferiority to latanoprost for reduction from baseline in mean diurnal IOP at Day 28.In pre-specified secondary efficacy analysis for reduction from baseline in mean diurnal IOP at Day 28, the mid and high doses of NCX 470 (0.042% and 0.065%) met the secondary efficacy endpoint of statistical superiority to latanoprost based on the study’s pre-specified statistical analysis plan.IOP reduction from baseline in mean diurnal IOP at Day 28 was 7.8 mmHg for the 0.021% dose of NCX 470 (p-value for NCX 470 vs. latanoprost not statistically significant); 8.2 mmHg for the 0.042% dose of NCX 470 (p-value for NCX 470 vs. latanoprost=0.0281); and 8.7 mmHg for the 0.065% dose of NCX 470 (p-value for NCX 470 v. latanoprost=0.0009).Dose response of IOP reduction from baseline in mean diurnal IOP at Day 28 showed improved increase in IOP lowering with each incremental concentration of NCX 470 tested, thus creating the potential for additional IOP lowering with a higher dose of NCX 470 which, subject to FDA agreement, may be tested in future clinical trials.Secondary Efficacy AnalysesIn additional pre-specified secondary efficacy analysis for reduction from baseline in mean diurnal IOP, NCX 470 (0.065%) met the secondary efficacy endpoint of statistical superiority to latanoprost at Day 7 (p=0.004) and Day 14 (p=0.0174), in addition to Day 28 (p=0.0009; described above)In pre-specified secondary efficacy analyses, the 0.065% dose of NCX 470 showed statistical superiority in IOP lowering as a reduction from baseline at all three time points (8 AM, 10 AM and 4 PM IOPs) on Day 28 compared with latanoprost, with the difference reaching up to 1.4 mmHg (p=0.0242 at 8 AM, p=0.0013 at 10 AM, and p=0.0016 at 4 PM).The IOP lowering effect as reduction from baseline at the three time points (8 AM, 10 AM and 4 PM IOPs) across Day 7, Day 14 and Day 28 ranged from 7.6 to 9.8 mmHg for the 0.065% concentration of NCX 470 compared with 6.3 to 8.8 mmHg for latanoprost.At Day 28, 44% of patients dosed with NCX 470 (0.065%) had a 1 mmHg or greater mean diurnal IOP reduction from baseline compared with the mean of 7.4 mmHg for the latanoprost group (p-value not significant); 37% of patients had 2 mmHg or greater reduction (p-value not significant); 27% had a 3 mmHg or greater reduction (p=0.0175); 16% had a 4 mmHg or greater reduction (p=0.0822); and 12% had a 5 mmHg or greater reduction (p=0.0150); compared with the mean for the latanoprost group.  Furthermore, greater proportion of patients dosed with NCX 470 (0.065%) achieved a mean diurnal IOP reduction at Day 28 of 40% or greater (p=0.0287), 35% or greater (p=0.0393), 30% or greater (p-value not statistically significant), 25% or greater (p=0.0479) and 20% or greater (p=0.0115), compared with those dosed with latanoprost.Safety and TolerabilityNCX 470 was well tolerated when dosed once daily for 28 days in patients with open-angle glaucoma or ocular hypertension.  Only three out of the 433 patients in the trial discontinued due to an adverse event. The majority adverse events in the study were mild.  The most frequent adverse event was conjunctival hyperemia, the majority of which were mild, in 16.8% of patients who dosed with the 0.065% dose of NCX 470 compared with 6.5% of patients who dosed with latanoprost.  Notably, adverse events for conjunctival hyperemia plateaued at the 0.042% concentration, for which it was reported for 22.2% of patients.  There were no treatment-related serious adverse events, and no evidence of treatment-related systemic side effects.Market ResearchIn order to understand the potential clinical adoption of NCX 470 for glaucoma and to assess its reimbursement and revenue potential, an independent third party market research agency with extensive experience in the ophthalmology market assessment conducted an initial primary market research study in the United States in the first half of 2019.  The market research was comprised of 40 interviews with U.S. ophthalmology key opinion leaders, high volume prescribers including ophthalmologists and optometrists, and third party payers.Multiple target product profiles of NCX 470 were tested with differentiation from each other by increasing superiority in IOP reduction compared to latanoprost 0.005%, based on a hypothetical statistically significant outcome in a head-to-head Phase 3 clinical study.  The varying levels of efficacy in the three target product profiles tested were chosen based on the current U.S. FDA-approved therapies.  For all three profiles, the safety and tolerability were identical and based on existing PGAs:A superiority to latanoprost similar to VYZULTA’s published Phase 2 VOYAGER study was selected for the first profile but with a superior U.S. FDA label based on head-to-head Phase 3 studies vs. PGA for NCX 470A superiority to latanoprost similar to the published ROCKLATAN Phase 3 Mercury-1 clinical study at month three but with improved safety and tolerability vs ROCKLATAN was selected for the second profileA ~2 mmHg or better superiority to latanoprost was selected for the third profile.The market research concluded that there was an opportunity for an impactful product with any of the three profiles tested and that the market potential increased with the size of the improved reduction in IOP:The VYZULTA-based product profile had peak U.S. net revenue potential of $230M (25% market share of the U.S. first-line therapy branded market).The Mercury-1 ROCKLATAN-based product potential but with improved safety and tolerability to ROCKLATAN had peak U.S. net revenue potential of $310M (35% market share of the U.S. first-line therapy branded market).The profile based on ~2 mmHg superiority to latanoprost had peak U.S. net revenue potential of $540M (60% market share of the U.S. first-line therapy branded market).The above forecasts include estimations about the future growth of the market and assume an appropriate level of reimbursement is available. AttachmentEN_NCX 470 Additional Results_20191022_Final 1

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Cookie Notice

We use cookies to improve your experience on our website

Information we collect about your use of Goldea Capital website

Goldea Capital website collects personal data about visitors to its website.

When someone visits our websites, we use a third party service, Google Analytics, to collect standard internet log information (such as IP address and type of browser they’re using) and details of visitor behavior patterns. We do this to allow us to keep track of the number of visitors to the various parts of the sites and understand how our website is used. We do not make any attempt to find out the identities or nature of those visiting our websites. We won’t share your information with any other organizations for marketing, market research or commercial purposes and we don’t pass on your details to other websites.

Use of cookies
Cookies are small text files that are placed on your computer or other device by websites that you visit. They are widely used to make websites work, or work more efficiently, as well as to provide information to the owners of the site.